The drug, currently approved for the treatment of osteoporosis, could prove to be a supplemental therapy to standard treatments like chemotherapy for those with certain head and neck cancers. Zoledronic acid halts bone resorption in osteoporosis patients by killing a bone-damaging cell.
Ohio State University scientists tested zoledronic acid on mice and found those treated with zoledronic acid fared better than the ones which were on a placebo treatment.
Osteoporosis is the leading type of bone disease that results in the thinning of bone tissue and significant loss of bone density. It affects some 28 million Americans.